These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 27475429)

  • 1. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
    Ruella M; June CH
    Curr Hematol Malig Rep; 2016 Oct; 11(5):368-84. PubMed ID: 27475429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
    Gill S; June CH
    Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 7. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.
    Jena B; Maiti S; Huls H; Singh H; Lee DA; Champlin RE; Cooper LJ
    PLoS One; 2013; 8(3):e57838. PubMed ID: 23469246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
    Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
    Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
    Gill S; Porter DL
    Expert Opin Biol Ther; 2014 Jan; 14(1):37-49. PubMed ID: 24261468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
    Cummins KD; Gill S
    Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
    Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
    Oh I; Oh Y; Ohmine K
    Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
    Avanzi MP; Brentjens RJ
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
    Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
    J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
    Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
    Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.